Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

التفاصيل البيبلوغرافية
العنوان: Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
المؤلفون: Gitelman, Stephen E, Bundy, Brian N, Ferrannini, Ele, Lim, Noha, Blanchfield, J Lori, DiMeglio, Linda A, Felner, Eric I, Gaglia, Jason L, Gottlieb, Peter A, Long, S Alice, Mari, Andrea, Mirmira, Raghavendra G, Raskin, Philip, Sanda, Srinath, Tsalikian, Eva, Wentworth, John M, Willi, Steven M, Krischer, Jeffrey P, Bluestone, Jeffrey A, Barr, Mayalin, Blanchfield, J Lori, Bluestone, Jeffrey A, Buchanan, Jeanne, Bundy, Brian N, Cabbage, Joanne, Coleman, Peter, De La Vega, Monica, DiMeglio, Linda A, Evans-Molina, Carmella, Felner, Eric I, Ferrannini, Ele, Ferrara, Christine, Gaglia, Jason L, Gitelman, Stephen E, Gottlieb, Peter A, Healy, Felicity, Higgins, Laurie, Hildinger, Megan, Jenkins, Margaret, Kayton Bryant, Nora, Kinderman, Amanda, Koshy, Nisha, Kost, Brianne, Krischer, Jeffrey P, Krishfield, Suzanne, Kucheruk, Olena, Lim, Noha, Lindsley, Karen, Long, S Alice, Mantravadi, Manasa, Mari, Andrea, Mesfin, Shelley, Michels, Aaron, Migre, Mary Ellen, Minnock, Pantea, Mirmira, Raghavendra G, Mohammed-Nur, Elham, Nelson, Jennifer, Nursing, Ashvin, O'Donnell, Ryan, Olivos, Diana, Parker, Melissa, Raskin, Philip, Redl, Leanne, Reed, Nicole, Resnick, Brittany, Sanda, Srinath, Sayre, Peter, Serti, Elisavet, Sims, Emily, Smith, Karen, Soppe, Carol, Stuart, Fiona, Szubowicz, Sarah, Tansey, Michel, Terrell, Jennifer, Tersey, Sarah, Torok, Christine, Tsalikian, Eva, Watson, Kelly, Wentworth, John M, Wesch, Rebecca, Willi, Steven, Woerner, Stephanie
المصدر: The Lancet Diabetes & Endocrinology; August 2021, Vol. 9 Issue: 8 p502-514, 13p
مستخلص: Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.
قاعدة البيانات: Supplemental Index
الوصف
تدمد:22138587
22138595
DOI:10.1016/S2213-8587(21)00139-X